Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 362

1.

The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.

Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.

Antivir Ther. 2007;12(3):407-15.

PMID:
17591031
[PubMed - indexed for MEDLINE]
2.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.

HIV Clin Trials. 2008 Nov-Dec;9(6):407-17. doi: 10.1310/hct0906-407.

PMID:
19203906
[PubMed - indexed for MEDLINE]
3.

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL.

J Antimicrob Chemother. 2009 Jun;63(6):1244-50. doi: 10.1093/jac/dkp100. Epub 2009 Mar 25.

PMID:
19321503
[PubMed - indexed for MEDLINE]
Free Article
4.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
[PubMed - indexed for MEDLINE]
5.

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team.

HIV Med. 2006 Mar;7(2):85-98.

PMID:
16420253
[PubMed - indexed for MEDLINE]
6.

Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.

Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A.

Pediatr Infect Dis J. 2008 Jan;27(1):17-21.

PMID:
18162932
[PubMed - indexed for MEDLINE]
7.

Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.

Claas GJ, Jülg B, Goebel FD, Bogner J.

Eur J Med Res. 2007 Feb 26;12(2):54-60.

PMID:
17369118
[PubMed - indexed for MEDLINE]
8.

Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.

McComsey GA, Lo Re V 3rd, O'Riordan M, Walker UA, Lebrecht D, Baron E, Mounzer K, Frank I.

Clin Infect Dis. 2008 Apr 15;46(8):1290-6. doi: 10.1086/529384.

PMID:
18444869
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.

Madruga JR, Cassetti I, Suleiman JM, Etzel A, Zhong L, Holmes CB, Cheng AK, Enejosa J; Study 903E Team.

HIV Clin Trials. 2007 Nov-Dec;8(6):381-90.

PMID:
18042503
[PubMed - indexed for MEDLINE]
Free Article
10.

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.

Llibre JM, Domingo P, Palacios R, Santos J, Pérez-Elías MJ, Sánchez-de la Rosa R, Miralles C, Antela A, Moreno S; Lipo-Rec Study Group.

AIDS. 2006 Jun 26;20(10):1407-14.

PMID:
16791015
[PubMed - indexed for MEDLINE]
11.

Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.

Schewe CK, Maserati R, Wassmer G, Adam A, Weitner L.

Clin Infect Dis. 2006 Jan 1;42(1):145-7. Epub 2005 Nov 29.

PMID:
16323105
[PubMed - indexed for MEDLINE]
Free Article
12.

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.

Elion R, Cohen C, Ward D, Ruane P, Ortiz R, Reddy YS, Ebrahimi R, McColl D, Kearney B, Fisher A, Flaherty J; BATON Study Group.

HIV Clin Trials. 2008 Jul-Aug;9(4):213-24. doi: 10.1310/hct0904-213.

PMID:
18753116
[PubMed - indexed for MEDLINE]
13.

CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G; Italian MASTER Cohort.

J Antimicrob Chemother. 2007 Jun;59(6):1141-7. Epub 2007 Apr 13.

PMID:
17434879
[PubMed - indexed for MEDLINE]
Free Article
14.

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G; Study 903 Team.

Nephrol Dial Transplant. 2005 Apr;20(4):743-6. Epub 2005 Mar 1.

PMID:
15741212
[PubMed - indexed for MEDLINE]
Free Article
15.

Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.

García-Benayas T, Rendón AL, Rodríguez-Novóa S, Barrios A, Maida I, Blanco F, Barreiro P, Rivas P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Apr;22(4):333-7.

PMID:
16623636
[PubMed - indexed for MEDLINE]
16.

Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.

Young B, Weidle PJ, Baker RK, Armon C, Wood KC, Moorman AC, Holmberg SD; HIV Outpatient Study (HOPS) Investigators.

AIDS Patient Care STDS. 2006 Apr;20(4):238-44.

PMID:
16623622
[PubMed - indexed for MEDLINE]
17.

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.

Rosen S, Long L, Fox M, Sanne I.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):334-44. doi: 10.1097/QAI.0b013e31817ae5ef.

PMID:
18545151
[PubMed - indexed for MEDLINE]
18.

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.

Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV.

AIDS. 2008 Oct 18;22(16):2155-63. doi: 10.1097/QAD.0b013e3283112b8e.

PMID:
18832879
[PubMed - indexed for MEDLINE]
19.

Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.

Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodriguez J, Vázquez G.

Antivir Ther. 2003 Jun;8(3):223-31.

PMID:
12924539
[PubMed - indexed for MEDLINE]
20.

Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.

Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, Amellal B, Bennai Y, Peytavin G, Calvez V, Pialoux G, Murphy R, Katlama C.

HIV Med. 2008 Oct;9(9):738-46. doi: 10.1111/j.1468-1293.2008.00616.x. Epub 2008 Jul 21.

PMID:
18651858
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk